Novo Nordisk launches affordable Ozempic alternative in South Africa as GLP-1 drugs gain traction across Africa
Danish pharma giant Novo Nordisk introduces cheaper authorised semaglutide copy in South Africa, signalling growing demand for diabetes and obesity treatments across the continent.